Insulin Degludec/Liraglutide
Brand name: Xultophy 100-3.6
Rank #452 of 500 drugs by total cost
$17.1M
Total Cost
10,644
Total Claims
$17.1M
Total Cost
483
Prescribers
$1,607
Cost per Claim
820
Beneficiaries
16,825
30-Day Fills
$35K
Avg Cost/Provider
22
Avg Claims/Provider
About Insulin Degludec/Liraglutide
Insulin Degludec/Liraglutide (sold as Xultophy 100-3.6) was prescribed 10,644 times by 483 Medicare Part D providers in 2023, costing the program $17.1M. At $1,607 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 449 | Vedolizumab (Entyvio) | $17.4M | 2,034 |
| 450 | Abatacept/Maltose (Orencia) | $17.2M | 3,809 |
| 451 | Potassium Citrate (Potassium Citrate Er) | $17.1M | 131,481 |
| 452 | Insulin Degludec/Liraglutide (Xultophy 100-3.6) | $17.1M | 10,644 |
| 453 | Dicyclomine Hcl (Dicyclomine Hcl) | $17.0M | 738,543 |
| 454 | Nitroglycerin (Nitroglycerin) | $16.8M | 768,384 |
| 455 | Lanreotide Acetate (Somatuline Depot) | $16.7M | 1,753 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology